Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
N-acetylglutamate synthase (NAGS) is a mitochondrial enzyme that catalyzes the formation of N-acetylglutamate from glutamate and acetyl-CoA, primarily in the liver[2][1]. N-acetylglutamate is a crucial allosteric activator of carbamoyl phosphate synthase I, the enzyme initiating the urea cycle for effective ammonia detoxification in mammals[1][2][3][4]. In microorganisms and plants, NAGS functions as a key enzyme for arginine biosynthesis[2][3]. Deficiency of NAGS causes a rare inborn error of metabolism—N-acetylglutamate synthase deficiency—resulting in impaired urea cycle function, potentially life-threatening hyperammonemia, and neurological symptoms[1][5]. Treatment with N-carbamylglutamate, a synthetic analog of N-acetylglutamate, can restore urea cycle activity and is an approved therapy for NAGS deficiency[5].
Allosteric activation of carbamoyl phosphate synthase I by production of N-acetylglutamate; Restoration of urea cycle function through N-carbamylglutamate supplementation in deficiency
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on N-acetylglutamate synthase (NAGS).